Navigation Links
Enterin's RASMET Study Enrolls First Patient With Parkinson's Disease
Date:5/15/2017

PHILADELPHIA, May 15, 2017 /PRNewswire/ -- Enterin Inc., a privately-held CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson's disease (PD), has enrolled the first patient in the RASMET study. The study is a Phase 1/2a randomized, controlled, multicenter study involving patients with PD and taking place at 12 US sites. It will enroll 50 patients over a 9-to-12-month period. The first stage is open label and involves single escalating doses in 10 patients with PD. Participating sites include Denver, Boca Raton, Tampa Bay and Cleveland. Details relating to the study can be found at ClinicalTrials.gov, and contact information is available on the Enterin website.

The study will establish the safety, tolerability and efficacy of an orally administered synthetic derivative of squalamine, which is not absorbed into the blood stream. The compound acts locally on the enteric nerve cells of the gut, stimulating gut motility and altering afferent neural signaling from gut to brain. It has the potential to ameliorate some or all of the non-motor symptoms of Parkinson's disease, including constipation, fragmented sleep and REM-behavior disorder, and to modify disease progression.

Synthetic squalamine was recently shown to prevent the buildup and reduce the toxicity of alpha-synuclein, implicated in the pathogenesis and progression of Parkinson's disease. The compound was shown to displace alpha-synuclein aggregates from the inner wall of nerve cells, and to prevent the stiffness which develops in C. Elegans worms engineered to produce alpha-synuclein in their muscles. The results were published online in the February 7th edition of the Proceedings of the National Academy of Sciences (Perni et al, PNAS Vol 114, no 6, 2017, doi: 10.1073/pnas.1610586114). Links to the article and to the press coverage can be found at the Enterin website.

About Enterin Inc.

Enterin Inc. is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (aS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. In the gut, this results in improved motility. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the constipation of Parkinson's disease. For more information, please visit www.enterininc.com.

Contact
Enterin Inc.
info@enterininc.com

Related Links

Website

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enterins-rasmet-study-enrolls-first-patient-with-parkinsons-disease-300457603.html


'/>"/>
SOURCE Enterin Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Getinge Announces Results of Study of Contemporary Practice Showing Larger Volume Intra-Aortic Balloon Effective as First-Line Therapy in Patients with Cardiogenic Shock
2. NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
3. Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
4. CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
5. Colitis Study Shows Curcumin More Powerful When Combined with Turmeric Essential Oil
6. Kaiser Permanente Study Tests New Way to Reduce Vaccine Hesitancy
7. Medivir Announces Positive Data From the Phase II Study of Remetinostat in Patients With Early-stage Cutaneous T-cell Lymphoma
8. MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)
9. HLT Announces First Patient Enrollments in a Feasibility Study of a New Transcatheter Aortic Valve Replacement System
10. Retrospective Study Confirms Bovine Carotid Artery Biologic Graft Outperforms Expanded Polytetrafluoroethylene for Hemodialysis Access
11. Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
Breaking Medicine News(10 mins):